Despite the reported and proven benefits of trastuzumab in HER2-overexpressing metastatic breast cancer patients, approximately 50% of them [7] exhibit de novo resistance while the vast majority of patients who initially respond eventually develop acquired resistance within a year [8]. The gene discussed is ERBB2; the disease is breast carcinoma.